Core Insights - Long-acting growth hormone, Longpei, developed by Weisheng Pharmaceutical, has shown strong commercial growth since its approval in Europe and the U.S. [1] - Longpei is the only long-acting growth hormone that continuously releases unmodified human growth hormone in the body between weekly doses, utilizing TransCon technology [1] - The product offers a convenient weekly dosing regimen, reducing injection frequency by 86% compared to daily formulations, and has demonstrated superior efficacy in clinical trials [1] - The approval of Longpei marks it as the third long-acting growth hormone approved in China for treating pediatric growth hormone deficiency (PGHD) [2] Company Insights - Weisheng Pharmaceutical is expected to enhance its commercialization framework based on the substantial progress of its innovative pipeline, positively impacting its growth prospects [1] - The introduction of Longpei fills a technological gap in the domestic market, which is primarily dominated by daily formulations, providing new treatment options for patients [1]
维昇药业-B核心产品隆培生长激素国内获批上市 周制剂创新有望重塑竞争格局